Please assess the completion status of the following clinical trial:

Trial Title: TYPE 2 HEPATORENAL SYNDROME

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Cirrhosis with ascites with serum creatinine more than 1.5 mg/dl and less than 2.5 mg/dl~2. Absence of shock, fluid losses and treatment with nephrotoxic drug~3. No improvement in renal function following diuretic withdrawal and plasma volume expansion~4. No ultrasound evidence of renal parenchymal disease or obstructive uropathy 5.Absence of proteinuria more than 500 mg/24 hour~Exclusion Criteria:~1. Patients with history of coronary artery disease~2. Cardiomyopathy~3. Ventricular arrhythmia~4. Obstructive arterial disease of limbs -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Terlipressin and Type-2 HRS (Type: ACTIVE_COMPARATOR): Patients in group A received terlipressin as an intravenous bolus of 0.5 mg every 6 h. If a significant reduction in serum creatinine level (≥1 mg/dL) was not observed during 3-day period, the dose of terlipressin was increased in a stepwise fashion every 3 days to a maximum of 2 mg every 6 hour.
- Noradrenaline and Type-2 HRS (Type: ACTIVE_COMPARATOR): Patients in group B received a continuous infusion of noradrenaline at an initial dose of 0.5 mg/hour, designed to achieve an increase in mean arterial pressure (MAP) of at least 10mmHg or an increase in 4-h urine output to more than 200 mL. When one of these goals was not achieved, the noradrenaline dose increased every 4 hour in steps of 0.5 mg/hour, up to the maximum dose of 3 mg/hour

Based on this trial design, predict the completion outcome and termination type (if applicable).